Protara Therapeutics (NASDAQ:TARA – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02, FiscalAI reports.
Protara Therapeutics Stock Up 8.0%
Shares of Protara Therapeutics stock opened at $2.30 on Friday. Protara Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.82. The business has a 50-day moving average price of $3.03 and a 200-day moving average price of $4.49. The firm has a market cap of $135.93 million, a price-to-earnings ratio of -1.65 and a beta of 1.54.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on TARA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.25.
Get Our Latest Stock Report on TARA
About Protara Therapeutics
Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.
Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.
Read More
- Five stocks we like better than Protara Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
